1. PI3K/Akt/mTOR
  2. PTEN
  3. BpV(HOpic)


Cat. No.: HY-128693 Purity: >95.0%
Handling Instructions

BpV(HOpic) is a potent and selective inhibitor of PTEN with an IC50 of 14 nM. Nanocarrier-BpV(HOpic) has neuroprotective activity.

For research use only. We do not sell to patients.

BpV(HOpic) Chemical Structure

BpV(HOpic) Chemical Structure

CAS No. : 722494-26-0

Size Price Stock Quantity
5 mg USD 325 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


BpV(HOpic) is a potent and selective inhibitor of PTEN with an IC50 of 14 nM. Nanocarrier-BpV(HOpic) has neuroprotective activity[1][2].

IC50 & Target

IC50: 14 nM (PTEN)[1]

In Vitro

BpV(HOpic) (1 µM) treatment increases cell proliferation and decreases apoptotic rate in MG63 cells received Cisplatin treatment[3].
Bpv(HOpic) (1 µM) enhances migration of C2C12 myoblasts and is associated with activation of PI3K/AKT and MAPK/ERK signalling pathways[4].
BpV(HOpic) (1 µM; 48 hours) promotes the initiation of swine follicle growth and development, similar as in rodent species and humans[5].
Nanocarrier-BpV(HOpic) enhances axonal outgrowth of neurons[2].

In Vivo

BpV(HOpic) (0.05 mg/kg; i.p.) at reperfusion ameliorates liver ischemia/reperfusion (I/R) injury in vivo[6].
BpV(HOpic) (200 μg/kg; i.p.) exacerbates renal dysfunction and promotes tubular damage in mice with ischemia/reperfusion injury (IRI)[7].

Animal Model: Male Wistar rats are subjected to partial hepatic ischemia[6]
Dosage: 0.05 mg/kg
Administration: I.p. injections at the start of reperfusion
Result: Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation.
Animal Model: Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia[7]
Dosage: 200 μg/kg
Administration: I.p. injections 1 h before ischemia and then administers every 6 h after ischemia for 24 hr
Result: Raised the level of serum creatinine and blood serum urea nitrogen.
Molecular Weight







O=[V+3]12([O-]3)([O-][O-]1)([O-][O-]2)[N]4=CC(O)=CC=C4C3=O.[2 K+]


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 55 mg/mL (158.39 mM; Need ultrasonic)

DMSO : 2.89 mg/mL (8.32 mM; Need ultrasonic)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8799 mL 14.3993 mL 28.7985 mL
5 mM 0.5760 mL 2.8799 mL 5.7597 mL
10 mM 0.2880 mL 1.4399 mL 2.8799 mL
*Please refer to the solubility information to select the appropriate solvent.

Purity: >95.0%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


BpV(HOpic)PTENPhosphatase and tensin homologMMAC1PI3K/AKTMAPK/ERKsignallingInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name



Applicant Name *


Email address *

Phone number *


Organization name *

Department *


Requested quantity *

Country or Region *



Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:
MCE Japan Authorized Agent: